SecBot SecBot
Biotech Drug Report Generated Nov 13, 2026

elsunersen

PRAX·Praxis Precision Medicines, Inc.
MIXED
Drug Impact Rating4/10
Trial phase
Phase 2/3 (registrational)
Time to market
If EMBRAVE3 topline results are positive, an NDA submission could follow in 2027, with potential FDA approval in 2028 given the Breakthrough Therapy and Rare Pediatric Disease designations that enable accelerated review.
Why 4/10
No hard dated binary catalyst (PDUFA or pivotal readout date) is scheduled for elsunersen in the next ~12 months; the EMBRAVE3 registrational topline readout was guided for 2026 but remains undated as of November 2026. The drug is also a third-priority asset behind relutrigine (PDUFA Dec 27, 2026) and ulixacaltamide (PDUFA Jan 29, 2027), which are the company's near-term value drivers.
Actionable Insight MIXED

Watch for EMBRAVE3 registrational topline results, which were expected in 2026 per the company's December 2025 guidance but have not yet been announced. Positive data would support an NDA filing; a miss or delay would push the timeline out significantly. The stock's near-term binary catalysts are relutrigine's PDUFA on December 27, 2026, and ulixacaltamide's PDUFA on January 29, 2027, which will likely dominate price action before elsunersen data emerges.

Price Chart

Loading chart...

Executive Summary

Elsunersen (PRAX-222) is Praxis Precision Medicines' antisense oligonucleotide for SCN2A gain-of-function developmental and epileptic encephalopathy (DEE), a rare genetic epilepsy in infants. Phase 2 EMBRAVE Part A results showed a 77% sham-adjusted seizure reduction (p=0.015) with a favorable safety profile, earning FDA Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations. The registrational EMBRAVE3 study was converted to a single-arm design with FDA agreement in December 2025, with topline results originally guided for 2026 but not yet reported as of November 2026. Elsunersen is a promising but later-stage pipeline asset behind Praxis' two lead programs (relutrigine and ulixacaltamide) that have PDUFA dates in late 2026 and early 2027.

How It Works

Elsunersen is an antisense oligonucleotide, a type of synthetic genetic medicine designed to reduce the production of the SCN2A protein. In patients with SCN2A gain-of-function mutations, the sodium channel protein is overactive, causing severe, hard-to-treat seizures starting in infancy. By lowering SCN2A gene expression, elsunersen aims to correct the underlying genetic imbalance and reduce seizure frequency.

Trial Status

EMBRAVE Part A (Phase 2, n=9) completed with positive topline results announced April 2026. EMBRAVE3, the single-arm registrational study, is ongoing with enrollment accelerating as of December 2025; topline results were expected in 2026 but have not yet been reported.

The Two-Sided Case

▲ Bull Case5
EMBRAVE Part A results were strong: 77% sham-adjusted reduction in monthly seizures (p=0.015), 71% of patients achieved >50% seizure reduction, and 57% had at least 28 days of seizure freedom.
Elsunersen holds FDA Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations, plus EMA PRIME and Orphan Drug designations, providing regulatory acceleration and potential priority review vouchers.
The FDA agreed to a simplified single-arm, baseline-controlled registrational pathway for EMBRAVE3, reducing trial complexity and cost.
No drug-related severe adverse events were reported in Part A; most side effects were mild to moderate, supporting a favorable safety profile.
Analyst consensus on PRAX is Strong Buy (24 buy/strong buy vs 2 hold/1 strong sell), with a mean price target of $661.75, implying ~104% upside from the current ~$318 price.
▼ Bear Case5
EMBRAVE3 registrational topline results were expected in 2026 but have not yet been reported as of November 2026, suggesting potential enrollment delays or data maturation issues.
Elsunersen is a third-priority pipeline asset behind relutrigine (PDUFA Dec 27, 2026) and ulixacaltamide (PDUFA Jan 29, 2027), so it may receive less management attention and capital allocation.
As an antisense oligonucleotide for a rare pediatric epilepsy, the addressable patient population (SCN2A gain-of-function DEE) is very small, limiting peak revenue potential.
The single-arm, open-label EMBRAVE3 design, while FDA-agreed, carries higher regulatory risk than a randomized controlled trial.
Wedbush maintains an Underperform rating on PRAX with a $189 price target, well below the current ~$318 stock price.

Upcoming Catalysts

  • EMBRAVE3 registrational topline results (expected 2026, no specific date announced)
  • Potential NDA submission following positive EMBRAVE3 data
  • FDA Rare Pediatric Disease priority review voucher eligibility upon NDA acceptance

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Praxis Precision Medicines, Inc. 8-K PRAX ·Originating report

Sources · 8

Hover a chip for the title
1 nasdaq.com2 nasdaq.com3 streetinsider.com4 msn.com5 markets.businessinsider.com6 tipranks.com7 seekingalpha.com8 msn.com